{"filing":{"accession_number":"0001493152-26-038649","cik":"0001401914","ticker":"DARE","company_name":"Dare Bioscience, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-14","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315226038649/form8-k.htm"},"events":[{"id":28140,"run_id":25723,"accession_number":"0001493152-26-038649","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Daré Bioscience announced a registered direct offering of 4,379,581 shares of common stock (or pre-funded warrants) at $1.37 per share, generating $6.0 million in gross proceeds, plus concurrent private placement of Series A and Series B warrants. The press release explicitly states the Series A and Series B warrants are being offered under Section 4(a)(2) of the Securities Act and Regulation D as an unregistered private placement. This is a classic dilutive equity issuance combining registered and unregistered securities to raise capital.","company_name":"Dare Bioscience, Inc.","ticker":"DARE","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29960,"accession_number":"0001493152-26-038649","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Daré Bioscience announced a registered direct offering of 4,379,581 shares of common stock (or pre-funded warrants) at $1.37 per share, generating $6.0 million in gross proceeds, plus concurrent private placement of Series A and Series B warrants. The press release explicitly states the Series A and Series B warrants are being offered under Section 4(a)(2) of the Securities Act and Regulation D as an unregistered private placement. This is a classic dilutive equity issuance combining registered and unregistered securities to raise capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:36:44.239699+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29960,"accession_number":"0001493152-26-038649","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Daré Bioscience announced a registered direct offering of 4,379,581 shares of common stock (or pre-funded warrants) at $1.37 per share, generating $6.0 million in gross proceeds, plus concurrent private placement of Series A and Series B warrants. The press release explicitly states the Series A and Series B warrants are being offered under Section 4(a)(2) of the Securities Act and Regulation D as an unregistered private placement. This is a classic dilutive equity issuance combining registered and unregistered securities to raise capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:36:44.239699+00:00","company_name":"Dare Bioscience, Inc.","ticker":"DARE","filing_date":"2026-08-17"}]}